Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Queensland Health
Chubb
Argus Health
Covington
Julphar

Generated: March 24, 2019

30 Drugs Facing Patent Expirations and Generic Entry in 2019 - 2020

Loss of Exclusivity / End of Market Exclusivity Period dates

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "30 Drugs Facing Patent Expirations and Generic Entry in 2019 - 2020" DrugPatentWatch.com thinkBiotech, 2019 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
TECFIDERA

Generic name: dimethyl fumarate
Patent Expiration / Generic Entry Opportunity April 01, 2019
Generic Entry Controlled by: Patent 6,509,376

TECFIDERA is a drug marketed by Biogen Idec Inc. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-nine patent family members in thirty-three countries. There has been litigation on patents covering TECFIDERA

See drug price trends for TECFIDERA.

The generic ingredient in TECFIDERA is dimethyl fumarate. There are seventy-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dimethyl fumarate profile page.

FLECTOR

Generic name: diclofenac epolamine
Patent Expiration / Generic Entry Opportunity April 13, 2019
Generic Entry Controlled by: Patent 5,607,690

Drug Price Trends for FLECTOR
FLECTOR is a drug marketed by Inst Biochem. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has ten patent family members in nine countries. There has been litigation on patents covering FLECTOR

See drug price trends for FLECTOR.

The generic ingredient in FLECTOR is diclofenac epolamine. There are forty-seven drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the diclofenac epolamine profile page.

CETROTIDE

Generic name: cetrorelix
Patent Expiration / Generic Entry Opportunity April 23, 2019
Generic Entry Controlled by: Patent 5,198,533

CETROTIDE is a drug marketed by Emd Serono Inc. There is one patent protecting this drug.

This drug has twenty-eight patent family members in twenty-two countries.

See drug price trends for CETROTIDE.

The generic ingredient in CETROTIDE is cetrorelix. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the cetrorelix profile page.

OMTRYG

Generic name: omega-3-acid ethyl esters type a
Patent Expiration / Generic Entry Opportunity April 23, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

OMTRYG is a drug marketed by Osmotica.

This drug has twenty-eight patent family members in twenty-two countries.

The generic ingredient in OMTRYG is omega-3-acid ethyl esters type a. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the omega-3-acid ethyl esters type a profile page.

BEVESPI AEROSPHERE

Generic name: formoterol fumarate; glycopyrrolate
Patent Expiration / Generic Entry Opportunity April 25, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

BEVESPI AEROSPHERE is a drug marketed by Astrazeneca Pharms. There are six patents protecting this drug.

This drug has one hundred and ten patent family members in twenty-seven countries.

See drug price trends for BEVESPI AEROSPHERE.

The generic ingredient in BEVESPI AEROSPHERE is formoterol fumarate; glycopyrrolate. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the formoterol fumarate; glycopyrrolate profile page.

OTOVEL

Generic name: ciprofloxacin hydrochloride; fluocinolone acetonide
Patent Expiration / Generic Entry Opportunity April 29, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

Drug Price Trends for OTOVEL
OTOVEL is a drug marketed by Laboratorios Salvat. There is one patent protecting this drug.

This drug has sixteen patent family members in thirteen countries.

See drug price trends for OTOVEL.

The generic ingredient in OTOVEL is ciprofloxacin hydrochloride; fluocinolone acetonide. There are thirty-four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ciprofloxacin hydrochloride; fluocinolone acetonide profile page.

BYVALSON

Generic name: nebivolol hydrochloride; valsartan
Patent Expiration / Generic Entry Opportunity June 03, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

Drug Price Trends for BYVALSON
BYVALSON is a drug marketed by Allergan Sales Llc. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in fifteen countries.

See drug price trends for BYVALSON.

The generic ingredient in BYVALSON is nebivolol hydrochloride; valsartan. There are fourteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the nebivolol hydrochloride; valsartan profile page.

RESCRIPTOR

Generic name: delavirdine mesylate
Patent Expiration / Generic Entry Opportunity June 07, 2019
Generic Entry Controlled by: Patent 6,177,101

RESCRIPTOR is a drug marketed by Viiv Hlthcare. There is one patent protecting this drug.

This drug has twenty-five patent family members in twenty countries.

See drug price trends for RESCRIPTOR.

The generic ingredient in RESCRIPTOR is delavirdine mesylate. One supplier is listed for this generic product. Additional details are available on the delavirdine mesylate profile page.

NATROBA

Generic name: spinosad
Patent Expiration / Generic Entry Opportunity June 22, 2019
Generic Entry Controlled by: Patent 6,342,482

Drug Price Trends for NATROBA
NATROBA is a drug marketed by Parapro Llc. There are three patents protecting this drug.

This drug has forty-eight patent family members in thirty countries.

See drug price trends for NATROBA.

The generic ingredient in NATROBA is spinosad. There is one drug master file entry for this API. Two suppliers are listed for this generic product. Additional details are available on the spinosad profile page.

KOVANAZE

Generic name: oxymetazoline hydrochloride; tetracaine hydrochloride
Patent Expiration / Generic Entry Opportunity June 29, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

KOVANAZE is a drug marketed by St Renatus. There are three patents protecting this drug.

This drug has twenty-three patent family members in thirteen countries.

The generic ingredient in KOVANAZE is oxymetazoline hydrochloride; tetracaine hydrochloride. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the oxymetazoline hydrochloride; tetracaine hydrochloride profile page.

FIRAZYR

Generic name: icatibant acetate
Patent Expiration / Generic Entry Opportunity July 15, 2019
Generic Entry Controlled by: Patent 5,648,333

FIRAZYR is a drug marketed by Shire Orphan Therap. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fourteen patent family members in thirty-three countries. There has been litigation on patents covering FIRAZYR

See drug price trends for FIRAZYR.

The generic ingredient in FIRAZYR is icatibant acetate. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the icatibant acetate profile page.

NOXAFIL

Generic name: posaconazole
Patent Expiration / Generic Entry Opportunity July 19, 2019
Generic Entry Controlled by: Patent 5,661,151

Drug Price Trends for NOXAFIL
NOXAFIL is a drug marketed by Merck Sharp Dohme and ScheringThere are nine patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and forty patent family members in thirty-four countries. There has been litigation on patents covering NOXAFIL

See drug price trends for NOXAFIL.

The generic ingredient in NOXAFIL is posaconazole. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the posaconazole profile page.

CARDIOTEC

Generic name: technetium tc-99m teboroxime kit
Patent Expiration / Generic Entry Opportunity July 28, 2019
Generic Entry Controlled by: Patent 6,056,941

CARDIOTEC is a drug marketed by Bracco. There is one patent protecting this drug.

This drug has ten patent family members in seven countries.

The generic ingredient in CARDIOTEC is technetium tc-99m teboroxime kit. There are four drug master file entries for this API. Additional details are available on the technetium tc-99m teboroxime kit profile page.

TROXYCA ER

Generic name: naltrexone hydrochloride; oxycodone hydrochloride
Patent Expiration / Generic Entry Opportunity August 19, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

TROXYCA ER is a drug marketed by Pfizer Inc. There are two patents protecting this drug.

This drug has fourteen patent family members in ten countries.

The generic ingredient in TROXYCA ER is naltrexone hydrochloride; oxycodone hydrochloride. There are nineteen drug master file entries for this API. Additional details are available on the naltrexone hydrochloride; oxycodone hydrochloride profile page.

YOSPRALA

Generic name: aspirin; omeprazole
Patent Expiration / Generic Entry Opportunity September 14, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

YOSPRALA is a drug marketed by Genus Lifesciences. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has forty-five patent family members in twenty-three countries. There has been litigation on patents covering YOSPRALA

See drug price trends for YOSPRALA.

The generic ingredient in YOSPRALA is aspirin; omeprazole. There are twenty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the aspirin; omeprazole profile page.

CYSTARAN

Generic name: cysteamine hydrochloride
Patent Expiration / Generic Entry Opportunity October 02, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

CYSTARAN is a drug marketed by Leadiant Biosci Inc.

This drug has forty-five patent family members in twenty-three countries.

See drug price trends for CYSTARAN.

The generic ingredient in CYSTARAN is cysteamine hydrochloride. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cysteamine hydrochloride profile page.

LUMASON

Generic name: sulfur hexafluoride lipid-type a microspheres
Patent Expiration / Generic Entry Opportunity October 10, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

LUMASON is a drug marketed by Bracco. There is one patent protecting this drug.

This drug has one hundred and forty-one patent family members in twenty-eight countries.

See drug price trends for LUMASON.

The generic ingredient in LUMASON is sulfur hexafluoride lipid-type a microspheres. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the sulfur hexafluoride lipid-type a microspheres profile page.

SYNRIBO

Generic name: omacetaxine mepesuccinate
Patent Expiration / Generic Entry Opportunity October 26, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

SYNRIBO is a drug marketed by Teva Pharms Intl. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-nine patent family members in nineteen countries.

See drug price trends for SYNRIBO.

The generic ingredient in SYNRIBO is omacetaxine mepesuccinate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the omacetaxine mepesuccinate profile page.

IONSYS

Generic name: fentanyl hydrochloride
Patent Expiration / Generic Entry Opportunity November 02, 2019
Generic Entry Controlled by: Patent 6,181,963

IONSYS is a drug marketed by The Medicines Co. There are twelve patents protecting this drug.

This drug has one hundred and seventy-five patent family members in thirty-three countries.

The generic ingredient in IONSYS is fentanyl hydrochloride. There are thirty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the fentanyl hydrochloride profile page.

SIMBRINZA

Generic name: brimonidine tartrate; brinzolamide
Patent Expiration / Generic Entry Opportunity December 07, 2019
Generic Entry Controlled by: Patent 6,316,441

Drug Price Trends for SIMBRINZA
SIMBRINZA is a drug marketed by Novartis Pharms Corp. There are three patents protecting this drug.

This drug has thirty-nine patent family members in twenty-four countries.

See drug price trends for SIMBRINZA.

The generic ingredient in SIMBRINZA is brimonidine tartrate; brinzolamide. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the brimonidine tartrate; brinzolamide profile page.

DUREZOL

Generic name: difluprednate
Patent Expiration / Generic Entry Opportunity December 13, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

Drug Price Trends for DUREZOL
DUREZOL is a drug marketed by Novartis Pharms Corp. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has six patent family members in five countries. There has been litigation on patents covering DUREZOL

See drug price trends for DUREZOL.

The generic ingredient in DUREZOL is difluprednate. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the difluprednate profile page.

VASCEPA

Generic name: icosapent ethyl
Patent Expiration / Generic Entry Opportunity January 27, 2020
Generic Entry Controlled by: Patent 8,188,146

Drug Price Trends for VASCEPA
VASCEPA is a drug marketed by Amarin Pharms. There are twenty-five patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and sixty-one patent family members in forty-one countries. There has been litigation on patents covering VASCEPA

See drug price trends for VASCEPA.

The generic ingredient in VASCEPA is icosapent ethyl. There are twelve drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the icosapent ethyl profile page.

POMALYST

Generic name: pomalidomide
Patent Expiration / Generic Entry Opportunity February 08, 2020
Generic Entry Controlled by: FDA Regulatory Exclusivity

POMALYST is a drug marketed by Celgene. There are fifteen patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and forty patent family members in forty-three countries. There has been litigation on patents covering POMALYST

See drug price trends for POMALYST.

The generic ingredient in POMALYST is pomalidomide. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pomalidomide profile page.

JUXTAPID

Generic name: lomitapide mesylate
Patent Expiration / Generic Entry Opportunity February 21, 2020
Generic Entry Controlled by: Patent 5,712,279

JUXTAPID is a drug marketed by Aegerion. There are nine patents protecting this drug.

This drug has ninety-two patent family members in thirty-seven countries. There has been litigation on patents covering JUXTAPID

See drug price trends for JUXTAPID.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lomitapide mesylate profile page.

QBREXZA

Generic name: glycopyrronium tosylate
Patent Expiration / Generic Entry Opportunity April 10, 2020
Generic Entry Controlled by: Patent 6,433,003

Drug Price Trends for QBREXZA
QBREXZA is a drug marketed by Dermira Inc. There are eight patents protecting this drug.

This drug has twenty-five patent family members in twelve countries.

See drug price trends for QBREXZA.

The generic ingredient in QBREXZA is glycopyrronium tosylate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the glycopyrronium tosylate profile page.

GATTEX KIT

Generic name: teduglutide recombinant
Patent Expiration / Generic Entry Opportunity April 14, 2020
Generic Entry Controlled by: Patent 5,789,379

GATTEX KIT is a drug marketed by Nps Pharms Inc. There are twenty-one patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-two patent family members in eighteen countries. There has been litigation on patents covering GATTEX KIT

The generic ingredient in GATTEX KIT is teduglutide recombinant. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the teduglutide recombinant profile page.

APTIVUS

Generic name: tipranavir
Patent Expiration / Generic Entry Opportunity April 29, 2020
Generic Entry Controlled by: Patent 5,852,195

Drug Price Trends for APTIVUS
APTIVUS is a drug marketed by Boehringer Ingelheim. There are three patents protecting this drug.

This drug has one hundred and fifty-six patent family members in thirty-one countries.

See drug price trends for APTIVUS.

The generic ingredient in APTIVUS is tipranavir. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tipranavir profile page.

VIVITROL

Generic name: naltrexone
Patent Expiration / Generic Entry Opportunity May 19, 2020
Generic Entry Controlled by: Patent 6,264,987

Drug Price Trends for VIVITROL
VIVITROL is a drug marketed by Alkermes. There are sixteen patents protecting this drug.

This drug has one hundred and twenty-three patent family members in twenty-eight countries. There has been litigation on patents covering VIVITROL

See drug price trends for VIVITROL.

The generic ingredient in VIVITROL is naltrexone. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the naltrexone profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Clients in 66 Countries

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
McKesson
QuintilesIMS
Moodys
Argus Health
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.